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ABSTRACT
Introduction: Self-monitoring of blood pressure is
effective in reducing blood pressure in hypertension.
However previous meta-analyses have shown a
considerable amount of heterogeneity between studies,
only part of which can be accounted for by
meta-regression. This may be due to differences in
design, recruited populations, intervention components
or results among patient subgroups. To further
investigate these differences, an individual patient data
(IPD) meta-analysis of self-monitoring of blood
pressure will be performed.
Methods and analysis: We will identify randomised
trials that have compared patients with hypertension who
are self-monitoring blood pressure with those who are
not and invite trialists to provide IPD including clinic and/
or ambulatory systolic and diastolic blood pressure at
baseline and all follow-up points where both intervention
and control groups were measured. Other data requested
will include measurement methodology, length of follow-
up, cointerventions, baseline demographic (age, gender)
and psychosocial factors (deprivation, quality of life),
setting, intensity of self-monitoring, self-monitored
blood pressure, comorbidities, lifestyle factors (weight,
smoking) and presence or not of antihypertensive
treatment. Data on all available patients will be included
in order to take an intention-to-treat approach. A two-
stage procedure for IPD meta-analysis, stratified by trial
and taking into account age, sex, diabetes and baseline
systolic BP will be used. Exploratory subgroup analyses
will further investigate non-linear relationships between
the prespecified variables. Sensitivity analyses will
assess the impact of trials which have and have not
provided IPD.
Ethics and dissemination: This study does not
include identifiable data. Results will be disseminated in
a peer-reviewed publication and by international
conference presentations.
Conclusions: IPD analysis should help the
understanding of which self-monitoring interventions
for which patient groups are most effective in the
control of blood pressure.
BACKGROUND
Across Europe and the USA, around 30% of
adults have or are being treated for hyperten-
sion, which is a key risk factor for cardiovascu-
lar disease, the largest cause of death
worldwide.1–4 Treatment of hypertension
through lowering blood pressure results in sig-
niﬁcant reductions in coronary artery disease
and stroke.5 Self-measurement of blood pres-
sure (BP) has been shown in randomised con-
trolled trials to reduce BP over and above
standard care.6 7 The improvements seen are
thought to be due to increased patient involve-
ment in their own treatment, resulting in
more effective hypertension management.8
Self-monitoring of BP is an increasingly
common part of hypertension management, is
well tolerated by patients and has been shown
to be a better predictor of end organ damage
than ofﬁce measurement.9–14
Previous systematic reviews and meta-
analyses have found that self-monitoring
reduces clinic BP by an average of around
4 mm Hg for systolic pressure and by around
1.5 mm Hg for diastolic pressure, small, but
Strengths and limitations of this study
▪ This study will gather all available individual
patient data from previous trials examining the
effectiveness of self-monitoring of blood pres-
sure in hypertension totalling up to 10 000 ran-
domised patients.
▪ It will be powered to compare the effectiveness
of self-monitoring in different subgroups which
was not previously possible.
▪ This study is inherently retrospective but all pro-
posed analyses will be agreed prior to conduct-
ing the investigation.
Tucker KL, et al. BMJ Open 2015;5:e008532. doi:10.1136/bmjopen-2015-008532 1
Open Access Protocol
signiﬁcant reductions compared to conventional
care.7 15 16 However, these analyses found signiﬁcant het-
erogeneity between the studies included (Systolic
I2=71.9%, Diastolic I2=42.1%) that could not be
accounted for by meta regression.16 Similar reductions
were seen in daytime ambulatory systolic BP monitor
(ABPM) but the small number of studies with such data
included in the previous analysis made interpretation
difﬁcult.16 17
Analysis by Bray et al suggested that when self-
monitoring was accompanied by a cointervention, parti-
cipants were more likely to meet target BP but this did
not explain remaining heterogeneity. Key issues in
understanding this include differences in study popula-
tions such as age, gender, body mass index (BMI), a pre-
vious cardiovascular event and socioeconomic situation.
Subgroup analyses from a previous summary
meta-analysis suggests that the observed heterogeneity
can be explained in part, due to cointerventions such as
telemonitoring and use of self-titration and the setting
in which the intervention is delivered.18 Further differ-
ences in intervention, comparators and outcome mea-
sures may be important and there may be subgroups of
patients for whom self-monitoring is of greater or
reduced beneﬁt.
An individual patient data meta-analysis of these data
may allow better discrimination of the causes of the
underlying heterogeneity.
METHODS
Aims and objectives
This study will undertake an individual patient data
meta-analysis of randomised trials of self-monitoring BP
using an intention-to-treat approach where possible. It
will assess the evidence for the effectiveness of self-
monitoring blood pressure, examine the effects of med-
iators of such effects and examine if particular sub-
groups would particularly beneﬁt from self-monitoring
intervention. In addition we will aim to develop a pro-
spective register of trials to facilitate on going analyses.
1. The primary objectives are to estimate the effect of
self-monitoring BP compared to standard care on:
– systolic and diastolic clinic BP at 12-month
follow-up
– systolic and diastolic ambulatory BP at 12 months
follow-up
– proportion controlled below the target speciﬁed in
the individual trial at 12 months follow-up
The effects at 6 and 18 months will also be examined
as the data allows as a secondary objective.
2. To use individual patient data to further explore the
heterogeneity found previously and to assess the
effect on outcome of the following where data allow:
length of follow-up, cointerventions, baseline demo-
graphic (age, gender) and psychosocial factors
(deprivation, quality of life), setting, intensity of self-
monitoring intervention, comorbidities (eg, history
of diabetes, cardiovascular disease, stroke), lifestyle
factors (diet, exercise, weight, smoking) and presence
or not of antihypertensive treatment and the number
of antihypertensive medications prescribed. This will
allow better deﬁnition of which intervention to use
with whom so as to better operationalise implementa-
tion of self-monitoring.
3. To develop a prospective register of trials to facilitate
on going meta-analysis.
Criteria for considering studies for the IPD meta-analysis
All published and unpublished controlled trials where
the authors are able to provide individual patient data
will be included that fulﬁl the following criteria:
▸ Population—patients with hypertension being
managed on an outpatient basis.
▸ Intervention—self-measurement of BP without medical
professional input plus or minus other
cointerventions.
▸ Comparator—no organised self-measurement of BP,
although there may be some ad hoc measurement
which would be difﬁcult to prevent or assess.
▸ Outcome—systolic and/or diastolic BP measured in
clinic, or by daytime ambulatory measurement.
▸ Study design—randomised trial of at least 100 partici-
pants followed up for at least 24 weeks.
▸ Publication Date since 2000 (because changes in the
technology used for self-monitoring make compari-
sons prior to this date less relevant).
Search strategy for identification of studies
Relevant electronic databases (MEDLINE, EMBASE,
Cochrane Library) will be searched for articles published
from 2000. The search strategy has been designed to
capture all the relevant literature concerning schedules
for self-monitoring of blood pressure. The MEDLINE
search strategy is given in online supplementary material
appendix A and searches of reference lists of all retrieved
papers will be performed. Articles for inclusion will
be assessed independently by two reviewers. Non-
randomised designs will be excluded. Data will be
extracted independently by two team members with dis-
agreements adjudicated by a third. We will study the refer-
ence lists of included articles and ask contributing
authors if they have, or are aware of any unpublished
data which might be included in the review.
Trial eligibility and methodological quality assessment
All published and unpublished controlled trials will be
included that assess self-measurement of BP without
medical professional input, if usual care did not include
organised self-monitoring and if a BP outcome was avail-
able that had been taken independently of self-
measurement (clinic or ambulatory measurement).
Assessment of the quality of included trials is controver-
sial.19 Self-monitoring studies are generally un-blinded for
obvious reasons. We will assess the quality of studies in
terms of the presence of randomisation, the methodology
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of outcome assessment, intention-to-treat analyses and
attrition rates.20 We will initially include all studies, and
then perform sensitivity analyses considering the potential
effect of excluding studies which may be confounded for
these reasons.
Data collection
Approaches will be made to all authors of trials that
meet the inclusion criteria. The following data will be
requested (if available);
Trial level data
▸ Setting (primary or secondary care)
▸ Population
– Inclusion and exclusion criteria
▸ Method of BP outcome measurement
– Monitor used
– Monitor validated?
– Arm used
– Number of readings used in analysis
– Other measurement criteria, for example, were
repeated readings at least 1 min apart?
▸ Details about randomisation
– Allocation groups
– Method of generation of randomisation list
– Method of concealment of randomisation
– Stratiﬁcation factors
▸ Intervention
– Details of training/education given (both for
control and intervention)
– Targets used for intervention and control groups;
if not speciﬁed for control concurrent national
target will be used
– Type and frequency of self-monitoring
– Any additional allocated intervention (ie, cointer-
vention including telemonitoring,
self-management)
– Who titrates medication (healthcare professional/
patient)
– Timing of trial follow-up appointments
▸ Details about cost of intervention
Individual patient data
▸ Demographic details
– Age and gender
▸ Medical history (speciﬁc comorbidities eg, diabetes,
cardiovascular disease)
▸ Number of medications prescribed at baseline and
follow-up
▸ BP readings (clinic, home and ambulatory where
available)
– Baseline
– Follow-up
▸ Allocation group
▸ Lifestyle factors
– Smoking
– Alcohol consumption
– Diet
– Weight
– Physical activity
▸ Psychosocial factors including
– Measures of deprivation, for example, Indices of
Multiple Deprivation
– Measures of anxiety and depression
– Measures of quality of life, for example, EQ-5D,
SF-36
▸ Patient satisfaction
▸ Costs
– Resource use
– Consultations
– Admissions
▸ Any new incidence of cardiovascular events or death
▸ Any clustering factors, for example, by practice
Data will be requested either in electronic or paper
form and a desired format and coding will be speciﬁed.
Trialists may supply data in the most convenient way
open to them provided details of coding are supplied.
The co-ordinating centre will ensure that data items are
consistently derived, labelled and coded. Each trial
group will be asked to nominate a trialist to lead in the
collaboration.
Data validation strategy
Original data will be transferred and stored in a secure
environment at the University of Oxford and copies will
be made for use in the analyses. Trial details and
summary measures will be cross-checked against pub-
lished articles by two reviewers and inconsistencies will
be discussed with the original trialist. Data from each
trial will remain the property of each individual group.
Outcome measures
The primary outcomes will be the change in mean
ofﬁce systolic and diastolic blood pressure, change in
ambulatory systolic and diastolic BP and proportion of
patients with ofﬁce BP below target between baseline
and follow-up. The primary outcome will be 12 months
and outcomes will also be assessed at 6 and 18 months.
Reporting of outcomes in the original trial report is not
an eligibility requirement provided data are available.
Data analysis
Data will be initially tabulated to include important attri-
butes of each trial and to assess comparability, for
example of treatment targets.
A two-stage procedure for IPD meta-analysis
(described below) will be adopted. Handling of missing
data will be by complete case analysis, with sensitivity
analyses using other methods including multiple imput-
ation if possible.
The two-stage analysis will use linear regression for con-
tinuous outcomes and logistic regression for proportions,
aggregated across studies by random effects inverse vari-
ance methods. Intention-to-treat comparisons of out-
comes between self-monitoring arm and comparator arm
will be summarised as forest plots with I2 statistics for
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heterogeneity. Analyses will be reported in subgroups, by
level of self-monitoring intervention. This will be deﬁned
according to levels based on those previously described
by Uhlig et al,21 as summarised in table 1. The level of
intervention examined in each included study will be
agreed by the co-ordinating centre and the relevant trial-
ists prior to conducting the analysis. Regression models
used in the primary analysis will be adjusted for patient
characteristics (including age and sex), baseline BP and
medical history, where appropriate.
Further analyses will explore the effects of age (in
10-year age bands), sex, BMI (dichotomised around BMI
of 30), baseline BP (in 10 mm Hg bands), number of
medications prescribed at baseline and the presence of
comorbidities at baseline (myocardial infarction, stroke,
diabetes, chronic kidney disease, obesity) on mean BP
change and BP control at follow-up. Exploratory analyses
will be conducted (where data are available) including
the use and nature of cointerventions (eg, aimed at
medication adherence vs behavioural change), planned
intensity of self-monitoring (ie, number of home read-
ings), psychosocial factors (eg, deprivation, quality of
life), setting and type of healthcare professional involved
(eg, pharmacist vs nurse vs physician), lifestyle factors
(eg, diet, smoking, alcohol consumption, physical activ-
ity) and changes in antihypertensive treatment at
follow-up and the impact on mean arterial BP (MAP).
In case of non-linear relationships between the prespe-
ciﬁed variables included in the model and outcome not
detected by regression, and to further explore relation-
ships where detected, these prespeciﬁed variables will be
further investigated in an exploratory analysis examining
the individual categories (quintiles in the case of con-
tinuous variables).
The potential for bias due to non-participation in the
IPD will be investigated by comparing aggregate data
from eligible trials with and without IPD.
Notwithstanding this and the impact of the inclusion cri-
teria (which exclude studies with small populations
and/or short follow-up), publication bias for the
primary outcome will be explored using Eggar’s
methods.22 For included trials a complete case analysis
approach will be used; sensitivity analyses will investigate
other methods including, if appropriate, multiple
imputation.
DISCUSSION
It is hoped that individual patient data analysis will allow
a greater understanding of observed between trial het-
erogeneity and lead to the identiﬁcation of the
characteristics of both the intervention and the indivi-
duals most likely to beneﬁt from self-monitoring of BP.
This will enhance understanding of self-monitoring of
BP and enable better targeted and more effective use of
this intervention.
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